Fremkomsten af HIV- resistens er set, når entecavir blev anvendt til behandling af kronisk hepatitis B- infektion hos patienter med HIV- infektion, som ikke fik antiretroviral kombinationsbehandling (highly active antiretroviral therapy - HAART) (se pkt.
Emergence of HIV resistance has been observed when entecavir was used to treat chronic hepatitis B infection in patients with HIV infection not receiving highly active antiretroviral therapy (HAART) (see section 5.1).